Omnes, an investment company, completed the acquisition of Biofutur, a group of medical biology analysis laboratories in Ile-de-France, for $66m. "We are proud to support Biofutur in its transformation, allowing it to take an important step in its development. This primary and non-intermediated deal perfectly illustrates our investment thesis of targeting solid mid-cap companies with ambitious management teams, and developing these platforms. The goal is to allow the company to double in size in the medium term. Our ability to structure a co-investment fund dedicated to the deal with leading partners confirms our analysis on this sector and more generally on the attractiveness of the health sector," Yoann Malys, Omnes Director.